NDC 36000-320-01 - Labetalol Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 36000-320
- Requested NDC
- 36000-320-01
- Package NDCs from labels
- 36000-320-01, 36000-320-10
- Manufacturer
- Baxter Healthcare Corporation | CAPLIN STERILES LIMITED
- Effective date
- 2020-07-24
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| LABETALOL - Baxter Healthcare Corporation | CAPLIN STERILES LIMITED | Baxter Healthcare Corporation | CAPLIN STERILES LIMITED | 2020-07-24 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 36000-320-01 | Labetalol Hydrochloride | 4 mL in 1 VIAL | INJECTION, SOLUTION | 4 | 6 | |
| 36000-320-10 | Labetalol Hydrochloride | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 6 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 36000-320-01 | ML - Milliliter | 36000-320 | b34ef2e5-e1d1-4c87-a0d3-882601c81f1a | 1 | 2021-05-05 |
| 36000-320-10 | ML - Milliliter | 36000-320 | 6134708c-3a79-4938-bc35-c888ef71af68 | 1 | 2021-05-05 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) | Fenwal, Inc. | 4a08a9ec-46a5-4fcf-80ee-5c33f1a8b746 | 2022-11-01 | XF417D3PSL | |
| LABETALOL HCl | LABETALOL HCL | HF Acquisition Co LLC, DBA HealthFirst | e76c4b37-4a34-249d-e053-2995a90aa9be | 2022-10-01 | Warnings, Adverse reactions | 896771 1GEV3BAW9J |
| Addiclenz | BETA VULGARIS, BOLDO, CHELIDONIUM MAJUS, PETROSELINUM SATIVUM, TARAXACUM OFFICINALE, ARSENICUM ALBUM, BISPHENOL A, COBALTUM METALLICUM, CUPRUM METALLICUM, GLYPHOSATE, IODIUM, LYCOPODIUM CLAVATUM, PHOSPHORICUM ACIDUM, SELENIUM METALLICUM, ZINCUM METALLICUM, ASPARTAME, BENZALKONIUM CHLORIDE, FORMALINUM, METHYLENE CHLORIDE, METHYL PARABEN, PROPYL PARABEN, SODIUM BENZOATE, SODIUM CITRATE, TITANIUM DIOXIDE, ZINCUM OXYDATUM | Deseret Biologicals, Inc. | e39235ea-2a2f-44a7-92d6-fb1d428ebabd | 2022-05-12 | Warnings | Z8IX2SC1OH A2I8C7HI9T |
| Bio Co-Enzyme Phase | BETA VULGARIS, ASCORBICUM ACIDUM, CYSTEINUM, NATRUM OXALACETICUM, NICOTINAMIDUM, PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, THIAMINUM HYDROCHLORICUM, ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CERIUM OXALICUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, NADIDUM, NATRUM PYRUVICUM, PANTOTHENIC ACID, SUCCINICUM ACIDUM, ADRENALINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, HEPAR SULPHURIS CALCAREUM, SULPHUR, ACONITICUM ACIDUM, CIS-, | Deseret Biologicals, Inc. | e8f6e2ec-ae2e-4bee-b9d3-5f3a2e3daf65 | 2022-05-09 | Warnings | XF417D3PSL |
| ACD Blood-Pack Units (PL 146 PLASTIC) | ANTICOAGULANT CITRATE DEXTROSE (ACD) | Fenwal, Inc. | ba894daa-688e-4a9e-bd74-e71797f951bb | 2022-04-27 | XF417D3PSL | |
| labetalol hydrochloride | LABETALOL HYDROCHLORIDE | Sagent Pharmaceuticals | da8af6c2-d822-4ae5-9c2d-a1d161bdefd0 | 2022-04-12 | Warnings, Adverse reactions | 896771 1GEV3BAW9J |
| Miracle FootCream Lavender | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db520c80-2a2a-5eb1-e053-2995a90a5bb4 | 2022-03-28 | Warnings | 7FLD91C86K |
| Miracle FootCream Lemon | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db525c63-29fd-2033-e053-2995a90a56b9 | 2022-03-28 | Warnings | 7FLD91C86K |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | XF417D3PSL | |
| Labetalol Hydrochloride | LABETALOL HYDROCHLORIDE | Epic Pharma, LLC | b950655d-a9f8-4ace-bb56-0c7abbca231e | 2021-09-30 | Warnings, Adverse reactions | 1GEV3BAW9J |
| Labetalol Hydrochloride | LABETALOL HYDROCHLORIDE | Hospira, Inc. | d3579d45-a964-40fe-e3a2-a3a997c8b7b9 | 2021-05-28 | Warnings, Adverse reactions | 1GEV3BAW9J |
| Labetalol Hydrochloride | LABETALOL HYDROCHLORIDE | Fosun Pharma USA Inc. | f18dff28-f6f5-4ecb-9797-25062e247559 | 2021-01-28 | Warnings, Adverse reactions | 896771 1GEV3BAW9J |
| Labetalol Hydrochloride | LABETALOL HYDROCHLORIDE | Baxter Healthcare Corporation | b17a7b3a-e7a5-4987-ae85-ad970e7540c7 | 2020-07-24 | Warnings, Adverse reactions | ANDA076051 36000-324-02 36000-320-01 36000-322-02 36000-320-10 36000-322-01 36000-324-01 36000-320 36000-324 36000-322 36000032001 896771 2477889 219d4dec-02d1-4d4b-88fd-01b1dbad3abc b17a7b3a-e7a5-4987-ae85-ad970e7540c7 1GEV3BAW9J |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | XF417D3PSL | |
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.